Genmab, Pfizer’s tisotumab vedotin takes a leap towards EU approval for cervical cancer
In a significant development for cervical cancer treatment, Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc. (NYSE: PFE) have announced the European Medicines Agency's (EMA) validation ... Read More
Advancing bladder cancer treatment: EMA scrutinizes Astellas-Pfizer’s innovative therapy
A groundbreaking development in bladder cancer treatment is on the horizon as Astellas Pharma Inc. and Pfizer Inc. await the European Medicines Agency’s (EMA) review ... Read More
Phase 3 EV-302 clinical trial : Seagen, Astellas reveal promising for PADCEV and KEYTRUDA combo
Seagen Inc. and Astellas Pharma Inc. have announced encouraging results from the Phase 3 EV-302 clinical trial, presenting PADCEV in combination with KEYTRUDA versus chemotherapy. ... Read More